PDCD1 and non-small cell lung carcinoma: In the present study, we showed that NSCLC patients treated with anti‐PD‐1/PD‐L1 inhibitors combined with chemotherapy achieved better PFS and OS than those treated with chemotherapy alone after progression on osimertinib.